Intergroup Exemestane Study (IES) results

Currently, five years of treatment with tamoxifen is considered the 'gold-standard' treatment for postmenopausal women with breast cancer. This drug blocks oestrogen, which can help fuel the growth of tumours in some cases.

Photo: Intergroup Exemestane Study (IES) results

Now, Instead of tamoxifen, many women are now given (orally) aromatase inhibitors following breast surgery. Aromatase inhibitors inhibit the enzyme aromatase, thus blocking oestrogen production.

According to the Intergroup Exemestane Study (IES) results, presented at the annual meeting of the American Society of Clinical Oncology in June, the drug aromasin, generically known as exemestane, and other aromatase inhibitors, cut the risk of death among some postmenopausal women with hormone-sensitive primary breast cancer by 17% compared with the standard tamoxifen treatment.

The UK-led five-year study involved over 4,700 post-menopausal women with early-stage  hormone-sensitive breast cancer, who were disease-free after taking tamoxifen for two to three years. Around 50% in the group remained on tamoxifen, whilst the rest were given Aromasin (2,372 women). Their progress was then tracked for about two-and-a-half years after treatment ended.
The researchers reported that the women who switched to Aromasin had a 17% lower risk of dying from the disease than those who continued on tamoxifen. Deaths: 210 in the Aromasin group; 251 in the tamoxifen group. In addition, the rate of tumours appearing in the opposite breast reduced by 44%.

01.07.2006

Read all latest stories

Related articles

Photo

Valid for breast as well as blood cancers

Surprising benefits discovered in new cancer treatment

One more piece of the puzzle has fallen into place behind a new drug whose anti-cancer potential was developed at the University of Alberta and is set to begin human trials this year, thanks to newly…

Photo

ER-positive tumour BC

Drug target for aggressive breast cancer found

A team of British and American scientists have discovered a way to slow the growth of breast cancer stem cells in the lab. The study led by Dr Bruno Simões and Professor Rob Clarke from The…

Photo

Triple-negative breast cancer

Target validation for drug development against aggressive breast cancer

At around 30.5 percent, breast cancer is the most common cancer among women in countries of the industrialized world. The number of cases has doubled since the 1980s: about 69,000 times a year women…

Related products

Hologic - I-View 2.0 Contrast Enhanced Imaging

Mammo Workstations

Hologic - I-View 2.0 Contrast Enhanced Imaging

Hologic, Inc.
Hologic - LOCalizer wire-free guidance system

Accessories / Complementary Systems

Hologic - LOCalizer wire-free guidance system

Hologic, Inc.
iCAD - Profound AI Risk

Artificial Intelligence

iCAD - Profound AI Risk

iCad
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH
Subscribe to Newsletter